Kohei Shitara

Research interests

Publications

• Gastric cancer

  The Lancet · 2025 · https://doi.org/10.1016/s0140-6736(25)00052-2

• Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00620-7

• Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00541-7

• Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)02033-0

• Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

  JAMA · 2023 · https://doi.org/10.1001/jama.2023.4428

• Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02465-7

• Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

  Nature · 2022 · 10.1038/s41586-022-04508-4

• Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

  Cancer Cell · 2022 · 10.1016/j.ccell.2022.01.001

• Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(21)00692-6

• First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00797-2

• Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

  Nature Reviews Clinical Oncology · 2021 · 10.1038/s41571-021-00492-2

• The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

  Nature · 2021 · https://doi.org/10.1038/s41586-021-04161-3

• Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

  JAMA Oncology · 2021 · 10.1001/jamaoncol.2021.0275

• Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

  JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.3370

• Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

  Journal of Clinical Oncology · 2020 · 10.1200/jco.19.03296

• The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

  Nature Immunology · 2020 · 10.1038/s41590-020-0769-3

• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004413

• Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

  Nature Reviews Clinical Oncology · 2019 · https://doi.org/10.1038/s41571-019-0175-7

• PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

  Proceedings of the National Academy of Sciences · 2019 · 10.1073/pnas.1822001116

• Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30791-5

• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

  Annals of Oncology · 2018 · 10.1093/annonc/mdy498

• Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31257-1

• Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30739-3

• Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.0013

• Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30604-6

• Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30111-0

• BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

  British Journal of Cancer · 2011 · 10.1038/bjc.2011.19

Current projects

No projects listed.